{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"nad-plus-stimulants","title":"NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers","body":"## What's breaking down if you have Stimulant load (Adderall / amphetamine)\n\nAmphetamines force dopamine and norepinephrine release. This borrows focus now.\n\nSleep, appetite, and gut lining often suffer. Less regeneration window follows.\n\nChronic load can deplete neurochemistry and stress the gut-brain axis.\n\nFour layers show the mismatch between breakdown and repair:\n\n- Dopamine system: Forced release leads to depletion, crash, anhedonia, and tolerance.\n- Sleep: Stimulants delay onset and cut deep sleep stages.\n- Gut: Mucosa faces stress; inflammation feeds back to mood and cognition.\n- Anxiety: Arousal without calm produces jitter, rumination, and non-restorative stress.\n\n## Why Semax might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. What keeps failing: BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\n3. What Semax is studied to do: Studied for BDNF and neural support — building connections, not sedating symptoms.\n4. Therefore for you: If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\n\n## Why Selank might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Anxiety — Arousal without calm leads to jitter, rumination, non-restorative stress.\n3. What Selank is studied to do: Studied for anxiolytic pathways without classic benzodiazepine sedation.\n4. Therefore for you: If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\n\n## Why DSIP might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Sleep — Stimulants delay sleep onset and cut deep sleep.\n3. What DSIP is studied to do: Studied for sleep architecture and deep-sleep promotion.\n4. Therefore for you: If that layer is part of your problem, DSIP is discussed because it targets repair (sleep / repair window) — not because it masks pain.\n\n## Why NAD+ might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Therefore for you: If that layer is part of your problem, NAD+ is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Amphetamine stimulants matters for you\n\n1. Drug: Amphetamine stimulants.\n2. What it does: Forces neurotransmitter release; borrows focus at cost of sleep/gut reserve.\n3. Therefore for you: This drug suppresses signals of fatigue and suppresses repair windows. It trades short-term focus for longer-term depletion of neurochemistry and sleep architecture.\n\n## How these fit together\n\nNeural support (Semax), non-benzo calm (Selank), sleep repair window (DSIP) — each targets a stimulant-degeneration layer.\n- Semax targets neural / cognitive.\n- Selank targets anxiety / neurochemistry.\n- DSIP targets sleep / repair window.\n- NAD+ targets cellular energy.\n\nThe stack maps distinct layers without overlap in primary action. Semax addresses BDNF and dopamine-related fatigue. Selank addresses arousal excess. DSIP widens the deep-sleep window stimulants shrink. NAD+ supports mitochondrial energy that stimulants can tax. Together they address separate points where breakdown exceeds repair.\n\n## What the evidence actually shows\n\nHuman data exist for Selank in generalized anxiety disorder. One trial compared it to medazepam in 62 patients and found comparable anxiolytic effects with additional cognitive benefits (source s12). Another small trial noted rapid response in some GAD patients (source s10).\n\nSemax has animal data showing increased BDNF in rat basal forebrain and hippocampus after intranasal dosing (source s6, source s0). A hypothesis paper links this to potential ADHD relevance via dopamine and BDNF pathways (source s1). One Russian pediatric report mentioned in secondary sources noted behavioral improvements in half of ADHD cases, but no large Western RCT confirms this (source s3, source s5).\n\nDSIP reduced amphetamine-induced hyperthermia in mice in one 1984 study (source s15). Human sleep studies are small and mixed; early trials reported increased delta sleep pressure in volunteers, yet results vary (source s16, source s18).\n\nNAD+ shows preclinical mitochondrial support and some observational links to addiction recovery pathways (source s19). Small older human reports on intravenous NAD for substance issues exist but lack modern controls (source s21). No direct human trials tie NAD+ specifically to amphetamine recovery.\n\n## What scientists say\n\nResearchers note Semax augments psychostimulant effects on dopamine in animals while raising BDNF (source s1). Selank trials emphasize GABAergic modulation without sedation (source s12). DSIP literature describes it as sleep-promoting rather than sedative (source s16). NAD+ reviews highlight its role in energy metabolism and potential in substance contexts, while calling for more controlled human data (source s19, source s20).\n\n## What people say on Reddit\n\nUsers report stacking Semax with Selank for focus and calm while on or after stimulants. Some describe improved task management and reduced jitter (source s29, source s32). DSIP threads mention deeper sleep perception. NAD+ appears in stacks for energy recovery but with variable subjective notes (source s33, source s34).\n\n## What people say on X\n\nLimited direct posts in available data; discussions echo Reddit patterns on peptide stacks for stimulant side effects, often anecdotal.\n\n## What we do not know\n\nNo large-scale Western randomized controlled trials exist for any of these compounds specifically in stimulant recovery populations. Human evidence for Semax in ADHD remains limited to non-English or small datasets. DSIP and NAD+ human data for this exact context stay sparse or absent. Long-term safety and interaction profiles with ongoing amphetamine use lack dedicated study.\n\n## Safety and limits\n\nAll compounds discussed here carry limited regulatory approval outside specific regions. Evidence grades remain mostly preclinical or small human for anxiety/sleep indications. Individual responses vary. This article inventories published observations only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/nad-plus-stimulants/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax increases BDNF levels in rat basal forebrain after intranasal application.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s6","s0"],"source_status":"sourced","why_material":"Supports neural repair layer discussion for stimulant-induced stress.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Selank showed anxiolytic effects comparable to medazepam in a trial of 62 GAD patients.","section":"Why Selank might help you","tier":"human","source_ids":["s12"],"source_status":"sourced","why_material":"Provides human evidence tier for anxiety layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSIP reduced amphetamine-induced hyperthermia in mice at certain doses.","section":"Why DSIP might help you","tier":"preclinical","source_ids":["s15"],"source_status":"sourced","why_material":"Direct animal link to amphetamine effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"NAD+ metabolism is implicated in addictive behavior and cravings in preclinical models.","section":"Why NAD+ might help you","tier":"preclinical","source_ids":["s19"],"source_status":"sourced","why_material":"Frames cellular energy repair vs stimulant depletion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Small human trials link intravenous NAD to substance use disorder recovery observations.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s21"],"source_status":"sourced","why_material":"Separates human observation from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996699/","title":"Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome","quote":"It has been found to stimulate memory and attention in rodents and humans after intranasal application.","summary":"Reviews Semax effects including BDNF in animals.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"51dd87e0e113556ec5d9779e7cf59758164f7e2f06e94cbfc0f537cfd6b9bf2a"},{"id":"s1","type":"review","url":"https://www.sciencedirect.com/science/article/abs/pii/S0306987706005391","title":"Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder","quote":"Evidence from animal studies revealed that Semax can augment the effects of psychostimulants on central dopamine release and also stimulates central brain-derived neurotrophic factor (BDNF) synthesis.","summary":"Proposes Semax for ADHD based on dopamine and BDNF data.","claim_ids":[],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"http_403","quote_status":"unverified","prev":"51dd87e0e113556ec5d9779e7cf59758164f7e2f06e94cbfc0f537cfd6b9bf2a","hash":"a3e825323e254a5b9692ae6b022a172b3ba3290c08aef75c1083e192be2a1c0c"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically to the rat basal forebrain","quote":"Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain","summary":"Direct rat BDNF measurement after Semax.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"a3e825323e254a5b9692ae6b022a172b3ba3290c08aef75c1083e192be2a1c0c","hash":"103bb95be0ebdba5074bbe9eb1f3e459dd77f0354a6812445e4ad3b90613fabd"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank","quote":"Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam","summary":"Human GAD trial results.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"103bb95be0ebdba5074bbe9eb1f3e459dd77f0354a6812445e4ad3b90613fabd","hash":"eb4e7d0f36c83146ac29868122a0152f698abd2bd2ff40c39437ad6f5ef5e333"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/6548818/","title":"DSIP reduces amphetamine-induced hyperthermia in mice","quote":"It was reported that DSIP reversed the increase in temperature of rats injected at room temperature with 15 mg d-amphetamine per kg body weight.","summary":"Animal thermoregulation data with amphetamine.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"eb4e7d0f36c83146ac29868122a0152f698abd2bd2ff40c39437ad6f5ef5e333","hash":"d86e27e1fa46e458b88d8f6b3839ca9f6d08d3ffc9e7e0ec465ab0c1563b446f"},{"id":"s19","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7278809/","title":"Sobriety and Satiety: Is NAD+ the Answer?","quote":"These studies implicate raising intracellular NAD+ levels as a potential target for managing and treating addictive behaviour and reducing cravings","summary":"Reviews NAD+ in addiction models.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"d86e27e1fa46e458b88d8f6b3839ca9f6d08d3ffc9e7e0ec465ab0c1563b446f","hash":"e33cbdf4c0839443ff3ef6f51ae5a232578dc850a4885d6c4530c48558f08aac"},{"id":"s21","type":"medical","url":"https://www.webmd.com/mental-health/addiction/nad-therapy-addiction","title":"NAD Therapy for Addiction: What to Know","quote":"The first study testing NAD for substance use disorders came out many decades ago. The doctor who did the study gave NAD in an IV to more than 100 people with alcohol use disorder, opioid use disorder, or other substance use disorders.","summary":"Summarizes historical NAD observations in substance issues.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"e33cbdf4c0839443ff3ef6f51ae5a232578dc850a4885d6c4530c48558f08aac","hash":"720177cd5370423ceab31b020bb4234735183b4dde2ea8cb3fd426b0a7a8263c"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:41:11.517Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers","register":"source_ledger","body":"## What's breaking down if you have Stimulant load (Adderall / amphetamine)\n\nAmphetamines force dopamine and norepinephrine release. This borrows focus now.\n\nSleep, appetite, and gut lining often suffer. Less regeneration window follows.\n\nChronic load can deplete neurochemistry and stress the gut-brain axis.\n\nFour layers show the mismatch between breakdown and repair:\n\n- Dopamine system: Forced release leads to depletion, crash, anhedonia, and tolerance.\n- Sleep: Stimulants delay onset and cut deep sleep stages.\n- Gut: Mucosa faces stress; inflammation feeds back to mood and cognition.\n- Anxiety: Arousal without calm produces jitter, rumination, and non-restorative stress.\n\n## Why Semax might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. What keeps failing: BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\n3. What Semax is studied to do: Studied for BDNF and neural support — building connections, not sedating symptoms.\n4. Therefore for you: If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\n\n## Why Selank might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Anxiety — Arousal without calm leads to jitter, rumination, non-restorative stress.\n3. What Selank is studied to do: Studied for anxiolytic pathways without classic benzodiazepine sedation.\n4. Therefore for you: If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\n\n## Why DSIP might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Sleep — Stimulants delay sleep onset and cut deep sleep.\n3. What DSIP is studied to do: Studied for sleep architecture and deep-sleep promotion.\n4. Therefore for you: If that layer is part of your problem, DSIP is discussed because it targets repair (sleep / repair window) — not because it masks pain.\n\n## Why NAD+ might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Therefore for you: If that layer is part of your problem, NAD+ is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Amphetamine stimulants matters for you\n\n1. Drug: Amphetamine stimulants.\n2. What it does: Forces neurotransmitter release; borrows focus at cost of sleep/gut reserve.\n3. Therefore for you: This drug suppresses signals of fatigue and suppresses repair windows. It trades short-term focus for longer-term depletion of neurochemistry and sleep architecture.\n\n## How these fit together\n\nNeural support (Semax), non-benzo calm (Selank), sleep repair window (DSIP) — each targets a stimulant-degeneration layer.\n- Semax targets neural / cognitive.\n- Selank targets anxiety / neurochemistry.\n- DSIP targets sleep / repair window.\n- NAD+ targets cellular energy.\n\nThe stack maps distinct layers without overlap in primary action. Semax addresses BDNF and dopamine-related fatigue. Selank addresses arousal excess. DSIP widens the deep-sleep window stimulants shrink. NAD+ supports mitochondrial energy that stimulants can tax. Together they address separate points where breakdown exceeds repair.\n\n## What the evidence actually shows\n\nHuman data exist for Selank in generalized anxiety disorder. One trial compared it to medazepam in 62 patients and found comparable anxiolytic effects with additional cognitive benefits (source s12). Another small trial noted rapid response in some GAD patients (source s10).\n\nSemax has animal data showing increased BDNF in rat basal forebrain and hippocampus after intranasal dosing (source s6, source s0). A hypothesis paper links this to potential ADHD relevance via dopamine and BDNF pathways (source s1). One Russian pediatric report mentioned in secondary sources noted behavioral improvements in half of ADHD cases, but no large Western RCT confirms this (source s3, source s5).\n\nDSIP reduced amphetamine-induced hyperthermia in mice in one 1984 study (source s15). Human sleep studies are small and mixed; early trials reported increased delta sleep pressure in volunteers, yet results vary (source s16, source s18).\n\nNAD+ shows preclinical mitochondrial support and some observational links to addiction recovery pathways (source s19). Small older human reports on intravenous NAD for substance issues exist but lack modern controls (source s21). No direct human trials tie NAD+ specifically to amphetamine recovery.\n\n## What scientists say\n\nResearchers note Semax augments psychostimulant effects on dopamine in animals while raising BDNF (source s1). Selank trials emphasize GABAergic modulation without sedation (source s12). DSIP literature describes it as sleep-promoting rather than sedative (source s16). NAD+ reviews highlight its role in energy metabolism and potential in substance contexts, while calling for more controlled human data (source s19, source s20).\n\n## What people say on Reddit\n\nUsers report stacking Semax with Selank for focus and calm while on or after stimulants. Some describe improved task management and reduced jitter (source s29, source s32). DSIP threads mention deeper sleep perception. NAD+ appears in stacks for energy recovery but with variable subjective notes (source s33, source s34).\n\n## What people say on X\n\nLimited direct posts in available data; discussions echo Reddit patterns on peptide stacks for stimulant side effects, often anecdotal.\n\n## What we do not know\n\nNo large-scale Western randomized controlled trials exist for any of these compounds specifically in stimulant recovery populations. Human evidence for Semax in ADHD remains limited to non-English or small datasets. DSIP and NAD+ human data for this exact context stay sparse or absent. Long-term safety and interaction profiles with ongoing amphetamine use lack dedicated study.\n\n## Safety and limits\n\nAll compounds discussed here carry limited regulatory approval outside specific regions. Evidence grades remain mostly preclinical or small human for anxiety/sleep indications. Individual responses vary. This article inventories published observations only.","claims":[{"id":"c1","text":"Semax increases BDNF levels in rat basal forebrain after intranasal application.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s6"],"source_status":"sourced","why_material":"Supports neural repair layer discussion for stimulant-induced stress.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Selank showed anxiolytic effects comparable to medazepam in a trial of 62 GAD patients.","section":"Why Selank might help you","tier":"human","source_ids":["s12"],"source_status":"sourced","why_material":"Provides human evidence tier for anxiety layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSIP reduced amphetamine-induced hyperthermia in mice at certain doses.","section":"Why DSIP might help you","tier":"preclinical","source_ids":["s15"],"source_status":"sourced","why_material":"Direct animal link to amphetamine effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"NAD+ metabolism is implicated in addictive behavior and cravings in preclinical models.","section":"Why NAD+ might help you","tier":"preclinical","source_ids":["s19"],"source_status":"sourced","why_material":"Frames cellular energy repair vs stimulant depletion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Small human trials link intravenous NAD to substance use disorder recovery observations.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s21"],"source_status":"sourced","why_material":"Separates human observation from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996699/","title":"Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome","quote":"It has been found to stimulate memory and attention in rodents and humans after intranasal application.","link_status":"ok","quote_status":"verified"},{"id":"s1","type":"review","url":"https://www.sciencedirect.com/science/article/abs/pii/S0306987706005391","title":"Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder","quote":"Evidence from animal studies revealed that Semax can augment the effects of psychostimulants on central dopamine release and also stimulates central brain-derived neurotrophic factor (BDNF) synthesis.","link_status":"http_403","quote_status":"unverified"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically to the rat basal forebrain","quote":"Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain","link_status":"ok","quote_status":"verified"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank","quote":"Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam","link_status":"ok","quote_status":"verified"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/6548818/","title":"DSIP reduces amphetamine-induced hyperthermia in mice","quote":"It was reported that DSIP reversed the increase in temperature of rats injected at room temperature with 15 mg d-amphetamine per kg body weight.","link_status":"ok","quote_status":"verified"},{"id":"s19","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7278809/","title":"Sobriety and Satiety: Is NAD+ the Answer?","quote":"These studies implicate raising intracellular NAD+ levels as a potential target for managing and treating addictive behaviour and reducing cravings","link_status":"ok","quote_status":"verified"},{"id":"s21","type":"medical","url":"https://www.webmd.com/mental-health/addiction/nad-therapy-addiction","title":"NAD Therapy for Addiction: What to Know","quote":"The first study testing NAD for substance use disorders came out many decades ago. The doctor who did the study gave NAD in an IV to more than 100 people with alcohol use disorder, opioid use disorder, or other substance use disorders.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":17978,"tokens_out":3611,"cost":0.0315,"prev_hash":"genesis","hash":"d74bbb8db3bc0837175920b54ed3caeb48650c6c09c87821303aca0afc74ab6a"}],"provenance":[{"ts":"2026-06-30T01:41:11.517Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: NAD Plus for Stimulants\nSlug: nad-plus-stimulants\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"multi_stack\",\"condition\":\"Stimulant load (Adderall / amphetamine)\",\"condition_key\":\"adderall-stimulant\",\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"},{\"id\":\"selank\",\"name\":\"Selank\"},{\"id\":\"dsip\",\"name\":\"DSIP\"},{\"id\":\"nad-plus\",\"name\":\"NAD+\"}],\"drugs_in_scope\":[\"adderall-amphetamine\"],\"weight_sensitive\":false,\"stimulant_context\":true,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Stimulant load (Adderall / amphetamine)\",\"degenerative_why\":[\"Amphetamines force dopamine and norepinephrine release — borrow focus now.\",\"Sleep, appetite, and gut lining often suffer — less regeneration window.\",\"Chronic load can deplete neurochemistry and stress the gut-brain axis.\"],\"degenerative_layers\":[{\"layer\":\"Dopamine system\",\"what_breaks\":\"Forced release → depletion → crash, anhedonia, tolerance.\"},{\"layer\":\"Sleep\",\"what_breaks\":\"Stimulants delay sleep onset and cut deep sleep.\"},{\"layer\":\"Gut\",\"what_breaks\":\"Stimulants stress mucosa; gut inflammation affects mood and cognition.\"},{\"layer\":\"Anxiety\",\"what_breaks\":\"Arousal without calm → jitter, rumination, non-restorative stress.\"}],\"note\":null},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"You have **Stimulant load (Adderall / amphetamine)** — breakdown is outpacing repair.\",\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Se","response":"{\n  \"slug\": \"nad-plus-stimulants\",\n  \"title\": \"NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers\",\n  \"body\": \"## What's breaking down if you have Stimulant load (Adderall / amphetamine)\\n\\nAmphetamines force dopamine and norepinephrine release. This borrows focus now.\\n\\nSleep, appetite, and gut lining often suffer. Less regeneration window follows.\\n\\nChronic load can deplete neurochemistry and stress the gut-brain axis.\\n\\nFour layers show the mismatch between breakdown and repair:\\n\\n- Dopamine system: Forced release leads to depletion, crash, anhedonia, and tolerance.\\n- Sleep: Stimulants delay onset and cut deep sleep stages.\\n- Gut: Mucosa faces stress; inflammation feeds back to mood and cognition.\\n- Anxiety: Arousal without calm produces jitter, rumination, and non-restorative stress.\\n\\n## Why Semax might help you\\n\\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\\n2. What keeps failing: BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n3. What Semax is studied to do: Studied for BDNF and neural support — building connections, not sedating symptoms.\\n4. Therefore for you: If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\\n\\n## Why Selank might help you\\n\\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\\n2. Layer breaking down: Anxiety — Arousal without calm leads to jitter, rumination, non-restorative stress.\\n3. What Selank is studied to do: Studied for anxiolytic pathways without classic benzodiazepine sedation.\\n4. Therefore for you: If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\\n\\n## Why DSIP might help you\\n\\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\\n2. Layer breaking down: Sleep — Stimulants delay slee","tokens_in":17978,"tokens_out":3611,"cost":0,"prev":"genesis","hash":"317f4f31293e6686d4248c47c6fce1f684db207a4227d0e93677da8d66ca60ff"},{"ts":"2026-07-17T02:40:44.998Z","model":"owner","action":"voxel_divide","prompt":"","input":"nad-plus-stimulants","response":"35 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"317f4f31293e6686d4248c47c6fce1f684db207a4227d0e93677da8d66ca60ff","hash":"94d293c7b33317da68cc1f491e1dfdcfaf13e2f517a0baffe27fd4994540539d"}],"energy":{"passes":2,"tokens_in":17978,"tokens_out":3611,"tokens_total":21589,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"94d293c7b33317da68cc1f491e1dfdcfaf13e2f517a0baffe27fd4994540539d"},"posted_at":"2026-06-29T21:32:44.696Z","created_at":"2026-06-29T21:32:44.696Z","updated_at":"2026-07-17T02:40:44.998Z","machine":{"shape":"article.machine/v1","slug":"nad-plus-stimulants","kind":"article","read":{"human":"https://miscsubjects.com/a/nad-plus-stimulants","json":"https://miscsubjects.com/api/articles/nad-plus-stimulants","bundle":"https://miscsubjects.com/api/articles/nad-plus-stimulants/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":7,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/nad-plus-stimulants/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=nad-plus-stimulants","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-stimulants\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-stimulants\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/nad-plus-stimulants/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"nad-plus-stimulants\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/nad-plus-stimulants | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/nad-plus-stimulants","json":"/api/articles/nad-plus-stimulants","markdown":"/api/articles/nad-plus-stimulants/bundle?format=markdown","skill":"/api/articles/nad-plus-stimulants/skill","topology":"/api/articles/nad-plus-stimulants/topology","versions":"/api/articles/nad-plus-stimulants/revisions","invocations":"/api/articles/nad-plus-stimulants/invocations"},"editorial_review":null,"editorial_audit":{"slug":"nad-plus-stimulants","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"e22b96a94ac17d0448c1e3a3bf48e33c42a9233cbcf68f93ed72555ab87beaf0","object":{"object_type":"article-object","identity":{"id":"article:nad-plus-stimulants","slug":"nad-plus-stimulants","title":"NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/nad-plus-stimulants","role":"explain","audience":"human"},"skill":{"route":"/api/articles/nad-plus-stimulants/skill","role":"direct behavior","audience":"model","content":"---\nname: nad-plus-stimulants\ndescription: Apply the NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers\n\nThis Skill is the behavioral expression of [the canonical article](/a/nad-plus-stimulants). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/nad-plus-stimulants.\n- Read claims and relationships at /api/articles/nad-plus-stimulants/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Stimulant load Adderall / amphetamine Amphetamines force dopamine and norepinephrine release. This borrows focus now. Sleep, appetite, and gut lining often suffer. Less regeneration window follows. Chronic l\n\n## Representations\n\n- Human: /a/nad-plus-stimulants\n- JSON: /api/articles/nad-plus-stimulants\n- Relationships: /api/articles/nad-plus-stimulants/topology\n- History: /api/articles/nad-plus-stimulants/revisions\n"},"json":{"route":"/api/articles/nad-plus-stimulants","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/nad-plus-stimulants/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","nad","plus","stimulants"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/nad-plus-stimulants/invocations?status=success","failure_events":"/api/articles/nad-plus-stimulants/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"nad-plus-stimulants","title":"NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers","body":"## What's breaking down if you have Stimulant load (Adderall / amphetamine)\n\nAmphetamines force dopamine and norepinephrine release. This borrows focus now.\n\nSleep, appetite, and gut lining often suffer. Less regeneration window follows.\n\nChronic load can deplete neurochemistry and stress the gut-brain axis.\n\nFour layers show the mismatch between breakdown and repair:\n\n- Dopamine system: Forced release leads to depletion, crash, anhedonia, and tolerance.\n- Sleep: Stimulants delay onset and cut deep sleep stages.\n- Gut: Mucosa faces stress; inflammation feeds back to mood and cognition.\n- Anxiety: Arousal without calm produces jitter, rumination, and non-restorative stress.\n\n## Why Semax might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. What keeps failing: BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\n3. What Semax is studied to do: Studied for BDNF and neural support — building connections, not sedating symptoms.\n4. Therefore for you: If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\n\n## Why Selank might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Anxiety — Arousal without calm leads to jitter, rumination, non-restorative stress.\n3. What Selank is studied to do: Studied for anxiolytic pathways without classic benzodiazepine sedation.\n4. Therefore for you: If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\n\n## Why DSIP might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Sleep — Stimulants delay sleep onset and cut deep sleep.\n3. What DSIP is studied to do: Studied for sleep architecture and deep-sleep promotion.\n4. Therefore for you: If that layer is part of your problem, DSIP is discussed because it targets repair (sleep / repair window) — not because it masks pain.\n\n## Why NAD+ might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Therefore for you: If that layer is part of your problem, NAD+ is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Amphetamine stimulants matters for you\n\n1. Drug: Amphetamine stimulants.\n2. What it does: Forces neurotransmitter release; borrows focus at cost of sleep/gut reserve.\n3. Therefore for you: This drug suppresses signals of fatigue and suppresses repair windows. It trades short-term focus for longer-term depletion of neurochemistry and sleep architecture.\n\n## How these fit together\n\nNeural support (Semax), non-benzo calm (Selank), sleep repair window (DSIP) — each targets a stimulant-degeneration layer.\n- Semax targets neural / cognitive.\n- Selank targets anxiety / neurochemistry.\n- DSIP targets sleep / repair window.\n- NAD+ targets cellular energy.\n\nThe stack maps distinct layers without overlap in primary action. Semax addresses BDNF and dopamine-related fatigue. Selank addresses arousal excess. DSIP widens the deep-sleep window stimulants shrink. NAD+ supports mitochondrial energy that stimulants can tax. Together they address separate points where breakdown exceeds repair.\n\n## What the evidence actually shows\n\nHuman data exist for Selank in generalized anxiety disorder. One trial compared it to medazepam in 62 patients and found comparable anxiolytic effects with additional cognitive benefits (source s12). Another small trial noted rapid response in some GAD patients (source s10).\n\nSemax has animal data showing increased BDNF in rat basal forebrain and hippocampus after intranasal dosing (source s6, source s0). A hypothesis paper links this to potential ADHD relevance via dopamine and BDNF pathways (source s1). One Russian pediatric report mentioned in secondary sources noted behavioral improvements in half of ADHD cases, but no large Western RCT confirms this (source s3, source s5).\n\nDSIP reduced amphetamine-induced hyperthermia in mice in one 1984 study (source s15). Human sleep studies are small and mixed; early trials reported increased delta sleep pressure in volunteers, yet results vary (source s16, source s18).\n\nNAD+ shows preclinical mitochondrial support and some observational links to addiction recovery pathways (source s19). Small older human reports on intravenous NAD for substance issues exist but lack modern controls (source s21). No direct human trials tie NAD+ specifically to amphetamine recovery.\n\n## What scientists say\n\nResearchers note Semax augments psychostimulant effects on dopamine in animals while raising BDNF (source s1). Selank trials emphasize GABAergic modulation without sedation (source s12). DSIP literature describes it as sleep-promoting rather than sedative (source s16). NAD+ reviews highlight its role in energy metabolism and potential in substance contexts, while calling for more controlled human data (source s19, source s20).\n\n## What people say on Reddit\n\nUsers report stacking Semax with Selank for focus and calm while on or after stimulants. Some describe improved task management and reduced jitter (source s29, source s32). DSIP threads mention deeper sleep perception. NAD+ appears in stacks for energy recovery but with variable subjective notes (source s33, source s34).\n\n## What people say on X\n\nLimited direct posts in available data; discussions echo Reddit patterns on peptide stacks for stimulant side effects, often anecdotal.\n\n## What we do not know\n\nNo large-scale Western randomized controlled trials exist for any of these compounds specifically in stimulant recovery populations. Human evidence for Semax in ADHD remains limited to non-English or small datasets. DSIP and NAD+ human data for this exact context stay sparse or absent. Long-term safety and interaction profiles with ongoing amphetamine use lack dedicated study.\n\n## Safety and limits\n\nAll compounds discussed here carry limited regulatory approval outside specific regions. Evidence grades remain mostly preclinical or small human for anxiety/sleep indications. Individual responses vary. This article inventories published observations only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/nad-plus-stimulants/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Semax increases BDNF levels in rat basal forebrain after intranasal application.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s6","s0"],"source_status":"sourced","why_material":"Supports neural repair layer discussion for stimulant-induced stress.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Selank showed anxiolytic effects comparable to medazepam in a trial of 62 GAD patients.","section":"Why Selank might help you","tier":"human","source_ids":["s12"],"source_status":"sourced","why_material":"Provides human evidence tier for anxiety layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSIP reduced amphetamine-induced hyperthermia in mice at certain doses.","section":"Why DSIP might help you","tier":"preclinical","source_ids":["s15"],"source_status":"sourced","why_material":"Direct animal link to amphetamine effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"NAD+ metabolism is implicated in addictive behavior and cravings in preclinical models.","section":"Why NAD+ might help you","tier":"preclinical","source_ids":["s19"],"source_status":"sourced","why_material":"Frames cellular energy repair vs stimulant depletion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Small human trials link intravenous NAD to substance use disorder recovery observations.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s21"],"source_status":"sourced","why_material":"Separates human observation from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996699/","title":"Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome","quote":"It has been found to stimulate memory and attention in rodents and humans after intranasal application.","summary":"Reviews Semax effects including BDNF in animals.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"51dd87e0e113556ec5d9779e7cf59758164f7e2f06e94cbfc0f537cfd6b9bf2a"},{"id":"s1","type":"review","url":"https://www.sciencedirect.com/science/article/abs/pii/S0306987706005391","title":"Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder","quote":"Evidence from animal studies revealed that Semax can augment the effects of psychostimulants on central dopamine release and also stimulates central brain-derived neurotrophic factor (BDNF) synthesis.","summary":"Proposes Semax for ADHD based on dopamine and BDNF data.","claim_ids":[],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"http_403","quote_status":"unverified","prev":"51dd87e0e113556ec5d9779e7cf59758164f7e2f06e94cbfc0f537cfd6b9bf2a","hash":"a3e825323e254a5b9692ae6b022a172b3ba3290c08aef75c1083e192be2a1c0c"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically to the rat basal forebrain","quote":"Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain","summary":"Direct rat BDNF measurement after Semax.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"a3e825323e254a5b9692ae6b022a172b3ba3290c08aef75c1083e192be2a1c0c","hash":"103bb95be0ebdba5074bbe9eb1f3e459dd77f0354a6812445e4ad3b90613fabd"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank","quote":"Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam","summary":"Human GAD trial results.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"103bb95be0ebdba5074bbe9eb1f3e459dd77f0354a6812445e4ad3b90613fabd","hash":"eb4e7d0f36c83146ac29868122a0152f698abd2bd2ff40c39437ad6f5ef5e333"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/6548818/","title":"DSIP reduces amphetamine-induced hyperthermia in mice","quote":"It was reported that DSIP reversed the increase in temperature of rats injected at room temperature with 15 mg d-amphetamine per kg body weight.","summary":"Animal thermoregulation data with amphetamine.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"eb4e7d0f36c83146ac29868122a0152f698abd2bd2ff40c39437ad6f5ef5e333","hash":"d86e27e1fa46e458b88d8f6b3839ca9f6d08d3ffc9e7e0ec465ab0c1563b446f"},{"id":"s19","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7278809/","title":"Sobriety and Satiety: Is NAD+ the Answer?","quote":"These studies implicate raising intracellular NAD+ levels as a potential target for managing and treating addictive behaviour and reducing cravings","summary":"Reviews NAD+ in addiction models.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"d86e27e1fa46e458b88d8f6b3839ca9f6d08d3ffc9e7e0ec465ab0c1563b446f","hash":"e33cbdf4c0839443ff3ef6f51ae5a232578dc850a4885d6c4530c48558f08aac"},{"id":"s21","type":"medical","url":"https://www.webmd.com/mental-health/addiction/nad-therapy-addiction","title":"NAD Therapy for Addiction: What to Know","quote":"The first study testing NAD for substance use disorders came out many decades ago. The doctor who did the study gave NAD in an IV to more than 100 people with alcohol use disorder, opioid use disorder, or other substance use disorders.","summary":"Summarizes historical NAD observations in substance issues.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:41:10.256Z","link_status":"ok","quote_status":"verified","prev":"e33cbdf4c0839443ff3ef6f51ae5a232578dc850a4885d6c4530c48558f08aac","hash":"720177cd5370423ceab31b020bb4234735183b4dde2ea8cb3fd426b0a7a8263c"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:41:11.517Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers","register":"source_ledger","body":"## What's breaking down if you have Stimulant load (Adderall / amphetamine)\n\nAmphetamines force dopamine and norepinephrine release. This borrows focus now.\n\nSleep, appetite, and gut lining often suffer. Less regeneration window follows.\n\nChronic load can deplete neurochemistry and stress the gut-brain axis.\n\nFour layers show the mismatch between breakdown and repair:\n\n- Dopamine system: Forced release leads to depletion, crash, anhedonia, and tolerance.\n- Sleep: Stimulants delay onset and cut deep sleep stages.\n- Gut: Mucosa faces stress; inflammation feeds back to mood and cognition.\n- Anxiety: Arousal without calm produces jitter, rumination, and non-restorative stress.\n\n## Why Semax might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. What keeps failing: BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\n3. What Semax is studied to do: Studied for BDNF and neural support — building connections, not sedating symptoms.\n4. Therefore for you: If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\n\n## Why Selank might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Anxiety — Arousal without calm leads to jitter, rumination, non-restorative stress.\n3. What Selank is studied to do: Studied for anxiolytic pathways without classic benzodiazepine sedation.\n4. Therefore for you: If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\n\n## Why DSIP might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Layer breaking down: Sleep — Stimulants delay sleep onset and cut deep sleep.\n3. What DSIP is studied to do: Studied for sleep architecture and deep-sleep promotion.\n4. Therefore for you: If that layer is part of your problem, DSIP is discussed because it targets repair (sleep / repair window) — not because it masks pain.\n\n## Why NAD+ might help you\n\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\n2. Therefore for you: If that layer is part of your problem, NAD+ is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why Amphetamine stimulants matters for you\n\n1. Drug: Amphetamine stimulants.\n2. What it does: Forces neurotransmitter release; borrows focus at cost of sleep/gut reserve.\n3. Therefore for you: This drug suppresses signals of fatigue and suppresses repair windows. It trades short-term focus for longer-term depletion of neurochemistry and sleep architecture.\n\n## How these fit together\n\nNeural support (Semax), non-benzo calm (Selank), sleep repair window (DSIP) — each targets a stimulant-degeneration layer.\n- Semax targets neural / cognitive.\n- Selank targets anxiety / neurochemistry.\n- DSIP targets sleep / repair window.\n- NAD+ targets cellular energy.\n\nThe stack maps distinct layers without overlap in primary action. Semax addresses BDNF and dopamine-related fatigue. Selank addresses arousal excess. DSIP widens the deep-sleep window stimulants shrink. NAD+ supports mitochondrial energy that stimulants can tax. Together they address separate points where breakdown exceeds repair.\n\n## What the evidence actually shows\n\nHuman data exist for Selank in generalized anxiety disorder. One trial compared it to medazepam in 62 patients and found comparable anxiolytic effects with additional cognitive benefits (source s12). Another small trial noted rapid response in some GAD patients (source s10).\n\nSemax has animal data showing increased BDNF in rat basal forebrain and hippocampus after intranasal dosing (source s6, source s0). A hypothesis paper links this to potential ADHD relevance via dopamine and BDNF pathways (source s1). One Russian pediatric report mentioned in secondary sources noted behavioral improvements in half of ADHD cases, but no large Western RCT confirms this (source s3, source s5).\n\nDSIP reduced amphetamine-induced hyperthermia in mice in one 1984 study (source s15). Human sleep studies are small and mixed; early trials reported increased delta sleep pressure in volunteers, yet results vary (source s16, source s18).\n\nNAD+ shows preclinical mitochondrial support and some observational links to addiction recovery pathways (source s19). Small older human reports on intravenous NAD for substance issues exist but lack modern controls (source s21). No direct human trials tie NAD+ specifically to amphetamine recovery.\n\n## What scientists say\n\nResearchers note Semax augments psychostimulant effects on dopamine in animals while raising BDNF (source s1). Selank trials emphasize GABAergic modulation without sedation (source s12). DSIP literature describes it as sleep-promoting rather than sedative (source s16). NAD+ reviews highlight its role in energy metabolism and potential in substance contexts, while calling for more controlled human data (source s19, source s20).\n\n## What people say on Reddit\n\nUsers report stacking Semax with Selank for focus and calm while on or after stimulants. Some describe improved task management and reduced jitter (source s29, source s32). DSIP threads mention deeper sleep perception. NAD+ appears in stacks for energy recovery but with variable subjective notes (source s33, source s34).\n\n## What people say on X\n\nLimited direct posts in available data; discussions echo Reddit patterns on peptide stacks for stimulant side effects, often anecdotal.\n\n## What we do not know\n\nNo large-scale Western randomized controlled trials exist for any of these compounds specifically in stimulant recovery populations. Human evidence for Semax in ADHD remains limited to non-English or small datasets. DSIP and NAD+ human data for this exact context stay sparse or absent. Long-term safety and interaction profiles with ongoing amphetamine use lack dedicated study.\n\n## Safety and limits\n\nAll compounds discussed here carry limited regulatory approval outside specific regions. Evidence grades remain mostly preclinical or small human for anxiety/sleep indications. Individual responses vary. This article inventories published observations only.","claims":[{"id":"c1","text":"Semax increases BDNF levels in rat basal forebrain after intranasal application.","section":"Why Semax might help you","tier":"preclinical","source_ids":["s6"],"source_status":"sourced","why_material":"Supports neural repair layer discussion for stimulant-induced stress.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Selank showed anxiolytic effects comparable to medazepam in a trial of 62 GAD patients.","section":"Why Selank might help you","tier":"human","source_ids":["s12"],"source_status":"sourced","why_material":"Provides human evidence tier for anxiety layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"DSIP reduced amphetamine-induced hyperthermia in mice at certain doses.","section":"Why DSIP might help you","tier":"preclinical","source_ids":["s15"],"source_status":"sourced","why_material":"Direct animal link to amphetamine effects.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"NAD+ metabolism is implicated in addictive behavior and cravings in preclinical models.","section":"Why NAD+ might help you","tier":"preclinical","source_ids":["s19"],"source_status":"sourced","why_material":"Frames cellular energy repair vs stimulant depletion.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Small human trials link intravenous NAD to substance use disorder recovery observations.","section":"What the evidence actually shows","tier":"anecdotal","source_ids":["s21"],"source_status":"sourced","why_material":"Separates human observation from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:41:11.121Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16996699/","title":"Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome","quote":"It has been found to stimulate memory and attention in rodents and humans after intranasal application.","link_status":"ok","quote_status":"verified"},{"id":"s1","type":"review","url":"https://www.sciencedirect.com/science/article/abs/pii/S0306987706005391","title":"Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder","quote":"Evidence from animal studies revealed that Semax can augment the effects of psychostimulants on central dopamine release and also stimulates central brain-derived neurotrophic factor (BDNF) synthesis.","link_status":"http_403","quote_status":"unverified"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16635254/","title":"Semax, an analogue of adrenocorticotropin (4-10), binds specifically to the rat basal forebrain","quote":"Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain","link_status":"ok","quote_status":"verified"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","title":"Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank","quote":"Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam","link_status":"ok","quote_status":"verified"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/6548818/","title":"DSIP reduces amphetamine-induced hyperthermia in mice","quote":"It was reported that DSIP reversed the increase in temperature of rats injected at room temperature with 15 mg d-amphetamine per kg body weight.","link_status":"ok","quote_status":"verified"},{"id":"s19","type":"other","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7278809/","title":"Sobriety and Satiety: Is NAD+ the Answer?","quote":"These studies implicate raising intracellular NAD+ levels as a potential target for managing and treating addictive behaviour and reducing cravings","link_status":"ok","quote_status":"verified"},{"id":"s21","type":"medical","url":"https://www.webmd.com/mental-health/addiction/nad-therapy-addiction","title":"NAD Therapy for Addiction: What to Know","quote":"The first study testing NAD for substance use disorders came out many decades ago. The doctor who did the study gave NAD in an IV to more than 100 people with alcohol use disorder, opioid use disorder, or other substance use disorders.","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":17978,"tokens_out":3611,"cost":0.0315,"prev_hash":"genesis","hash":"d74bbb8db3bc0837175920b54ed3caeb48650c6c09c87821303aca0afc74ab6a"}],"provenance":[{"ts":"2026-06-30T01:41:11.517Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: NAD Plus for Stimulants\nSlug: nad-plus-stimulants\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"multi_stack\",\"condition\":\"Stimulant load (Adderall / amphetamine)\",\"condition_key\":\"adderall-stimulant\",\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"},{\"id\":\"selank\",\"name\":\"Selank\"},{\"id\":\"dsip\",\"name\":\"DSIP\"},{\"id\":\"nad-plus\",\"name\":\"NAD+\"}],\"drugs_in_scope\":[\"adderall-amphetamine\"],\"weight_sensitive\":false,\"stimulant_context\":true,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Stimulant load (Adderall / amphetamine)\",\"degenerative_why\":[\"Amphetamines force dopamine and norepinephrine release — borrow focus now.\",\"Sleep, appetite, and gut lining often suffer — less regeneration window.\",\"Chronic load can deplete neurochemistry and stress the gut-brain axis.\"],\"degenerative_layers\":[{\"layer\":\"Dopamine system\",\"what_breaks\":\"Forced release → depletion → crash, anhedonia, tolerance.\"},{\"layer\":\"Sleep\",\"what_breaks\":\"Stimulants delay sleep onset and cut deep sleep.\"},{\"layer\":\"Gut\",\"what_breaks\":\"Stimulants stress mucosa; gut inflammation affects mood and cognition.\"},{\"layer\":\"Anxiety\",\"what_breaks\":\"Arousal without calm → jitter, rumination, non-restorative stress.\"}],\"note\":null},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"You have **Stimulant load (Adderall / amphetamine)** — breakdown is outpacing repair.\",\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Se","response":"{\n  \"slug\": \"nad-plus-stimulants\",\n  \"title\": \"NAD+ and Related Peptides for Stimulant Load: Evidence on Repair Layers\",\n  \"body\": \"## What's breaking down if you have Stimulant load (Adderall / amphetamine)\\n\\nAmphetamines force dopamine and norepinephrine release. This borrows focus now.\\n\\nSleep, appetite, and gut lining often suffer. Less regeneration window follows.\\n\\nChronic load can deplete neurochemistry and stress the gut-brain axis.\\n\\nFour layers show the mismatch between breakdown and repair:\\n\\n- Dopamine system: Forced release leads to depletion, crash, anhedonia, and tolerance.\\n- Sleep: Stimulants delay onset and cut deep sleep stages.\\n- Gut: Mucosa faces stress; inflammation feeds back to mood and cognition.\\n- Anxiety: Arousal without calm produces jitter, rumination, and non-restorative stress.\\n\\n## Why Semax might help you\\n\\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\\n2. What keeps failing: BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n3. What Semax is studied to do: Studied for BDNF and neural support — building connections, not sedating symptoms.\\n4. Therefore for you: If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\\n\\n## Why Selank might help you\\n\\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\\n2. Layer breaking down: Anxiety — Arousal without calm leads to jitter, rumination, non-restorative stress.\\n3. What Selank is studied to do: Studied for anxiolytic pathways without classic benzodiazepine sedation.\\n4. Therefore for you: If that layer is part of your problem, Selank is discussed because it targets repair (anxiety / neurochemistry) — not because it masks pain.\\n\\n## Why DSIP might help you\\n\\n1. You have Stimulant load (Adderall / amphetamine) — breakdown is outpacing repair.\\n2. Layer breaking down: Sleep — Stimulants delay slee","tokens_in":17978,"tokens_out":3611,"cost":0,"prev":"genesis","hash":"317f4f31293e6686d4248c47c6fce1f684db207a4227d0e93677da8d66ca60ff"},{"ts":"2026-07-17T02:40:44.998Z","model":"owner","action":"voxel_divide","prompt":"","input":"nad-plus-stimulants","response":"35 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"317f4f31293e6686d4248c47c6fce1f684db207a4227d0e93677da8d66ca60ff","hash":"94d293c7b33317da68cc1f491e1dfdcfaf13e2f517a0baffe27fd4994540539d"}],"energy":{"passes":2,"tokens_in":17978,"tokens_out":3611,"tokens_total":21589,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"94d293c7b33317da68cc1f491e1dfdcfaf13e2f517a0baffe27fd4994540539d"},"posted_at":"2026-06-29T21:32:44.696Z","created_at":"2026-06-29T21:32:44.696Z","updated_at":"2026-07-17T02:40:44.998Z","machine":{"shape":"article.machine/v1","slug":"nad-plus-stimulants","kind":"article","read":{"human":"https://miscsubjects.com/a/nad-plus-stimulants","json":"https://miscsubjects.com/api/articles/nad-plus-stimulants","bundle":"https://miscsubjects.com/api/articles/nad-plus-stimulants/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":7,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/nad-plus-stimulants/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=nad-plus-stimulants","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-stimulants\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-stimulants\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/nad-plus-stimulants/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"nad-plus-stimulants\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/nad-plus-stimulants | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/nad-plus-stimulants","json":"/api/articles/nad-plus-stimulants","markdown":"/api/articles/nad-plus-stimulants/bundle?format=markdown","skill":"/api/articles/nad-plus-stimulants/skill","topology":"/api/articles/nad-plus-stimulants/topology","versions":"/api/articles/nad-plus-stimulants/revisions","invocations":"/api/articles/nad-plus-stimulants/invocations"},"editorial_review":null,"editorial_audit":{"slug":"nad-plus-stimulants","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"e22b96a94ac17d0448c1e3a3bf48e33c42a9233cbcf68f93ed72555ab87beaf0"}}}